Troglitazone
Troglitazone
Troglitazone (pronounced: troh-GLIH-tuh-zone) is a type of antidiabetic medication that was used to treat Type 2 diabetes. It belongs to the class of drugs known as thiazolidinediones.
Etymology
The name "Troglitazone" is derived from the chemical structure of the drug, which includes a troglitazone ring and a thiazolidinedione moiety.
Usage
Troglitazone was primarily used to improve glycemic control in patients with Type 2 diabetes. It works by increasing the sensitivity of liver, muscle, and fat cells to insulin, allowing these cells to take in and store glucose more effectively.
Side Effects
Like all medications, Troglitazone can cause side effects. The most common side effects include headache, flu-like symptoms, and muscle pain. In rare cases, Troglitazone can cause more serious side effects, such as liver damage and heart failure.
Withdrawal from Market
Troglitazone was withdrawn from the market in 2000 due to concerns about its potential to cause liver damage. It was replaced by other thiazolidinediones, such as pioglitazone and rosiglitazone, which have a lower risk of liver toxicity.
Related Terms
- Thiazolidinediones: A class of drugs used to treat Type 2 diabetes.
- Insulin: A hormone that regulates the amount of glucose in the blood.
- Liver damage: A condition that can occur as a side effect of certain medications, including Troglitazone.
- Heart failure: A condition that can occur as a side effect of certain medications, including Troglitazone.
External links
- Medical encyclopedia article on Troglitazone
- Wikipedia's article - Troglitazone
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski